Fortrea Holdings Earnings Call Signals Steady Turnaround

Fortrea Holdings Inc. ((FTRE)) has held its Q4 earnings call. Read on for the main highlights of the call.

Fortrea Holdings Inc. struck a cautiously optimistic tone in its latest earnings call, pairing tangible progress on cash generation, cost cuts and debt reduction with clear acknowledgment of ongoing revenue pressure. Management framed 2026 as another transition year, emphasizing improved EBITDA and cash flow while warning that top-line recovery and margin normalization will be gradual and uneven.

Revenue Edges Higher for 2025 but Q4 Soft

Full-year 2025 revenue came in at $2,723.4 million, up about 1% year over year and in line with guidance, underscoring disciplined execution despite industry headwinds. However, fourth-quarter revenue of $660.5 million fell 5.2% versus the prior year, reflecting softer activity in key lines of business.

Cash Generation Strengthens and Collections Improve Sharply

Fortrea delivered a strong finish to the year on cash, with Q4 operating cash flow of $129.1 million and free cash flow of $121.6 million, driving full-year figures to $113.5 million and $88.3 million respectively. Day sales outstanding fell to just 16 days, an improvement of 17 days sequentially and 24 days year over year, highlighting much tighter working-capital management.

Cost-Savings Program Outperforms Expectations

The company exceeded its 2025 cost-savings targets, generating approximately $153 million in gross savings and $93 million in net savings. These actions supported margins and underpinned the improvement in cash flow, forming a key pillar of Fortrea’s multi-year turnaround plan.

Balance Sheet Deleveraging and Liquidity Cushion

Fortrea continued to chip away at leverage, repaying about $75.7 million of senior secured notes in Q4 using cash on hand and bringing total debt reduction since the spin to roughly 35% of the original balance. The company ended the quarter with no borrowings on its revolver and more than $600 million of available liquidity, giving it flexibility despite revenue volatility.

Backlog and Book-to-Bill Signal Healthier Demand

Commercial indicators showed a gradual demand improvement, with Q4 book-to-bill at 1.14 times and trailing 12-month book-to-bill at 1.02 times. Backlog reached $7.7 billion and cancellations stayed in line with historical patterns, suggesting a stabilizing base of future work even as near-term revenue remains pressured.

Adjusted EBITDA Holds Up in a Tough Environment

Full-year adjusted EBITDA was $189.9 million, landing toward the high end of guidance and demonstrating resilience in profitability. In Q4, adjusted EBITDA of $54 million was slightly below the prior year’s $56 million, reflecting a relatively stable performance despite revenue decline and mix challenges.

Operational Wins and Commercial Momentum

The company highlighted notable Q4 wins, including a long-term clinical pharmacology partnership with a top-five pharmaceutical company and multiple functional service provider renewals. Fortrea also booked a healthy mix of Phase II and Phase III global clinical development projects, while Net Promoter Scores and employee engagement improved year over year, pointing to better client and workforce sentiment.

AI and Technology Investments Start to Pay Off

Fortrea is leaning into its accelerate platform and AI-enabled tools such as an AI risk radar, a CRA mobile app, the My Day platform and feasibility intelligence pilots to boost productivity. Management cited concrete outcomes, including cutting recruitment time by about three months in a complex respiratory trial and fully enrolling a Phase II Alzheimer’s study, underscoring the operational impact of these investments.

Leadership Team Deepens Bench Strength

The company expanded its leadership ranks with the addition of Aggie Gallagher as general counsel and Dr. Scott Dave to lead clinical pharmacology. In parallel, Dr. Oren Cohen is now serving full time as chief medical officer, a move aimed at sharpening Fortrea’s scientific engagement with biopharma clients.

Quarterly Revenue Decline Highlights Ongoing Headwinds

The 5.2% year-over-year decline in Q4 revenue to $660.5 million was driven largely by lower pass-through costs in clinical pharmacology and clinical development and continued FSP headwinds. This drop underscores the sensitivity of reported revenue to mix and pass-through trends, even as underlying demand metrics improve.

FSP and Pass-Through Variability Pressure Top Line

Management emphasized that the functional service provider business remains under pressure and that pass-through revenue is inherently lumpy, particularly after one-time high pass-through studies in 2024 rolled off. These dynamics are key drivers behind current volatility and the expected year-over-year revenue decline projected for 2026.

Profitability Squeezed as Adjusted Net Income Falls

Profitability metrics reflected these headwinds, with Q4 adjusted net income dropping to $9.2 million from $16.6 million a year earlier. While the Q4 net loss narrowed to $32.5 million and adjusted EBITDA declined only modestly, the results show that improving margins remains an ongoing challenge.

2026 Revenue Guidance Points to Decline

Management guided 2026 revenue to a range of $2.55 billion to $2.65 billion, implying a year-over-year decline from 2025 levels. The pressure stems primarily from the phasing of prior bookings, continuing FSP softness and expected reductions in pass-through costs, even as underlying backlog appears solid.

Cash Flow Seasonality to Weigh on Early 2026

While Fortrea expects full-year 2026 operating cash flow to be positive, management cautioned that the first quarter will likely be cash-flow negative. The hit will come from variable compensation payouts and a partial reversal of timing-related DSO benefits, though the company anticipates these effects will be more than offset by cash generation in subsequent quarters.

Customer Concentration Adds a Layer of Risk

The company disclosed that its top 10 customers accounted for 56.8% of 2025 revenue, with the largest client alone contributing 18.1%. This level of customer concentration heightens exposure to any change in spending patterns or contract decisions from a small number of key accounts.

Margin Recovery Framed as Multi-Year Journey

Fortrea reiterated that adjusted EBITDA and margin expansion will unfold over several years, relying on both sustainable revenue growth and continued structural cost actions. Management views peer-level, mid-teens margins as a longer-term ambition rather than a near-term outcome, reinforcing the notion that this is an extended turnaround.

Cash Flow Lower Versus 2024 but Better on Like-for-Like Basis

Full-year 2025 operating cash flow of $113.5 million and free cash flow of $88.3 million were down sharply from 2024’s $262.8 million and $237.3 million, at first glance suggesting deterioration. However, 2024 benefited from securitization proceeds, and on a comparable basis management said cash flow improved by roughly $148 million, marking real underlying progress.

Guidance and Outlook: Incremental Progress Amid Revenue Pressure

For 2026, Fortrea is guiding to $2.55–$2.65 billion in revenue and adjusted EBITDA of $190–$220 million, alongside a target of positive full-year operating cash flow. The company plans an additional $70–80 million in gross cost savings ($40–50 million net), continued debt paydown, and expects liquidity to remain strong, while margins are projected to grind higher through the year as part of a multi-year push toward mid-teens levels.

Fortrea’s earnings call painted the picture of a company executing well on what it can control—costs, cash and balance sheet—while navigating real but manageable revenue headwinds. For investors, the story remains one of gradual recovery: EBITDA and cash flow are improving, the pipeline and backlog look healthier, yet top-line and margin normalization will likely arrive in measured steps rather than in a single breakout year.